[In vitro activity of commercially available disinfectants against Stenotrophomonas maltophilia]

V Majtán1, L Majtánová

  • 1Slovenská zdravotnícka univerzita, Ustav preventívnej a klinickej medicíny, Bratislava, Slovenská republika.

Insights

This study evaluated 14 disinfectants against Stenotrophomonas maltophilia, finding significant variations in antibacterial efficacy. Benzalconium chloride and Triquart showed the highest activity, while others demonstrated moderate to low effectiveness and varying impacts on cellular processes.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Biochemistry

Context:

  • Stenotrophomonas maltophilia is a significant hospital-acquired pathogen.
  • Disinfectant efficacy is crucial for infection control in healthcare settings.
  • Quaternary ammonium compounds (QACs) are widely used disinfectants.

Purpose:

  • To assess the in vitro antibacterial efficacy of 14 commercial disinfectants against Stenotrophomonas maltophilia.
  • To categorize disinfectants based on their Minimum Inhibitory Concentration (MIC) and ED50 values.
  • To investigate the impact of disinfectants on bacterial biosynthetic processes, including nucleic acid and protein synthesis.

Summary:

  • Four groups of disinfectants were defined based on their activity against S. maltophilia, with benzalconium chloride and Triquart exhibiting the highest efficacy (MIC 0.045-0.09 µg/ml).
  • Combination formulations showed varied MICs, ranging from 0.19 to 100 µg/ml.
  • Disinfectants differentially affected bacterial biosynthesis; R values < 1 indicated potential inhibition of nucleic acid and protein synthesis by specific formulations, and endogenous respiration was inhibited at varying concentrations.

Impact:

  • Provides crucial data for selecting effective disinfectants against Stenotrophomonas maltophilia in healthcare environments.
  • Highlights the varying mechanisms of action of QAC-based disinfectants on bacterial cellular processes.
  • Informs infection control strategies and disinfectant development for combating hospital-acquired infections.